Tuesday, 05 July 2022

Zydus bags DCGI approval for 'anaemia associated with CKD' drug Oxemia

07 March 2022 | News

The drug to be launched soon is a breakthrough treatment for anaemia in patients suffering from CKD

Image credit: Shutterstock

Image credit: Shutterstock

Zydus Lifesciences has received approval for its New Drug Application (NDA) from the Drug Controller General of India for Oxemia (Desidustat), a first-of-its-kind oral treatment in India for anaemia associated with Chronic Kidney Disease (CKD).


Oxemia is an oral, small molecule hypoxia-inducible factor-prolyl hydroxylase (HIF-PH) inhibitor. Desidustat met its primary endpoints for haemoglobin improvement in the DREAM- D and DREAM-ND Phase III clinical trials and showed a good safety profile, downregulation of hepcidin, improved iron mobilisation and LDL-C reduction in CKD patients.


The clinical development programme of Desidustat was one of the largest trials of its kind in India for anemia in CKD patients, conducted in over 1200 subjects. Desidustat provides CKD patients with an oral convenient therapeutic option for the treatment of anaemia.


× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account